Skip to main content

Published locations for Risankizumab compared with secukinumab in 52-week psoriasis trial

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Risankizumab compared with secukinumab in 52-week psoriasis trial

User login

  • Reset your password
  • /content/risankizumab-compared-secukinumab-52-week-psoriasis-trial
  • /edermatologynews/article/224333/psoriasis/risankizumab-compared-secukinumab-52-week-psoriasis-trial
  • /rheumatologynews/article/224333/psoriasis/risankizumab-compared-secukinumab-52-week-psoriasis-trial
  • /rheumatology/article/224333/psoriasis/risankizumab-compared-secukinumab-52-week-psoriasis-trial
  • /dermatology/article/224333/psoriasis/risankizumab-compared-secukinumab-52-week-psoriasis-trial
  • /psoriatic-arthritis-icymi/article/224333/psoriasis/risankizumab-compared-secukinumab-52-week